Verstecktes Gen in Bevölkerungen des Nahen Ostens kann Parkinson-Krankheit signalisieren

A groundbreaking international study has uncovered a hidden genetic factor linked to Parkinson’s disease among Middle Eastern populations, highlighting critical gaps in current treatment strategies. Researchers from the US National Institute on Ageing and the German Centre for Neurodegenerative Diseases examined the genetic risk profiles of over 100,000 individuals, revealing that people of Middle Eastern descent exhibit distinct patterns of genetic variation associated with the condition. Parkinson’s disease, a progressive neurological disorder, affects motor function and often leads to complications involving sleep, mental health, and other physiological systems. The study, published in The Lancet Neurology, found that Middle Eastern populations show higher frequencies of specific genetic variants connected to the disease. Among those of Middle Eastern ancestry, a causal variant in the LRRK2 gene was identified in 4.4 percent of Parkinson’s patients, more than twice the average observed in the general study group. Additionally, the PRKN gene variant, known to drive early-onset Parkinson’s, was detected in 1.3 percent of participants. These findings underscore a lack of representation in existing genetic studies, which predominantly focus on European populations. As a result, gene-targeted therapies designed for Western demographics may not effectively address the unique genetic makeup of Middle Eastern communities. Dr. Lara Lange, a co-author of the study and fellow at the National Institute on Ageing Laboratories of Neurogenetics, emphasized that approximately 12 percent of Middle Eastern Parkinson’s patients carry identifiable genetic variants, primarily in LRRK2 and GBA1, that could be targets for emerging precision medicines. Despite this, she noted that most clinical trials for these treatments remain concentrated in North America and Europe, leaving a gap in therapeutic accessibility for Middle Eastern patients. Globally, Parkinson’s disease-related disability and mortality have increased dramatically, rising from three million cases in 1990 to an estimated twelve million by 2025. The prevalence of the disease in the Middle East stands at about 83 per 100,000 people, though these numbers are expected to climb due to aging populations and shifting lifestyles. Dr. Muhammad Ghatali, a neurologist at Mubadala Health in Dubai, explained that while Parkinson’s cannot be entirely prevented, understanding genetic predispositions allows for earlier intervention. He noted that clinicians typically rely on symptom-based diagnosis, such as loss of smell or movement difficulties, but in younger patients, genetic testing becomes crucial. Treatment options include traditional medications like levodopa, which remains the gold standard, alongside newer approaches such as MRI-guided focused ultrasound, offering a one-time solution for managing tremors. Dr. Ghatali highlighted the potential for the United Arab Emirates to play a pivotal role in global Parkinson’s research, citing its ethnically diverse population as an ideal setting for studying how genetic and biological factors interact across different ancestral backgrounds. Public health initiatives beyond clinical research are also essential in reducing the disease’s impact. Efforts to improve early detection, expand access to specialized care, and promote lifestyle modifications, including regular physical activity, are gaining traction. These measures aim to alleviate the growing burden of Parkinson’s disease in the Arabian Gulf, ensuring that both genetic insights and community-based interventions work together to enhance patient outcomes.